Article Text

Download PDFPDF
Importance of molecular testing in dominant optic atrophy
  1. N Patel1,
  2. A J Churchill1,
  3. C Toomes2,
  4. N J Marchbank2,
  5. C F Inglehearn2,
  6. N Foulds3,
  7. A Moosavi4,
  8. M Teimory4
  1. 1Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK
  2. 2Molecular Medicine Unit, University of Leeds, Leeds LS9 7TF, UK
  3. 3St George’s Hospital and School of Medicine, London SW17 4QX, UK
  4. 4West Sussex Eye Unit, Worthing and St Richard’s Hospital, West Sussex, BN112DF, UK
  1. Correspondence to: Dr Patel; drnish1975{at}yahoo.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Juvenile onset dominant optic atrophy (DOA) is the most common inherited optic atrophy with a variable prevalence of between 1 in 10 000 (Denmark) and 1 in 50 000.1,2 The majority of cases have been shown to have mutations in the OPA1 gene on chromosome 3.3–5 Reduced visual acuity of insidious onset, temporal pallor of the optic disc, centrocaecal scotoma, and generalised dyschromatopsia are the key clinical features.6 Recent studies, however, have shown that penetrance within families is much lower than first realised and the assignment of status using clinical criteria alone can result …

View Full Text